Release date: 2016-09-19 Scientists have recently developed a drug that can effectively kill malignant pancreatic cancer without accompanying obvious side effects. The drug is called "IMM-101", which awakens the body's immune system to kill tumors. Since pancreatic cancer will actively escape the identification of the immune system in the natural state, the emergence of this drug is of great significance for the treatment of this type of tumor. Researchers from the University of London in the United Kingdom have found that they can effectively kill peripheral cells of pancreatic cancer cells and prolong the lifespan of patients with metastatic pancreatic cancer by combining IMM-101 with the existing chemotherapy drug gemcitabine. “This is very exciting for me,†said lead researcher Angus Dalgleish. “This is the first time we have found an immunotherapy that can help control pancreatic cancer.†Patients receiving this immunotherapeutic treatment indicated that they were more comfortable than traditional chemotherapy. Moreover, the results of the study indicate that the therapy has no obvious side effects. Although the results of the early studies are very gratifying, this does not mean that the drug has the ability to cure pancreatic cancer. Moreover, since the experiment included only 110 patients, it was also necessary to increase the number of samples to obtain more reliable results. Dalgleish has been studying IMM-101 for a long time. Previously, it has shown that it has a certain therapeutic effect on skin cancer and lung cancer. However, in view of the long-standing refractory phenomenon of pancreatic cancer, the recent research has more significance. Researchers are currently planning to conduct further research on a larger scale to fully validate the results obtained before. The current lifespan of patients with advanced pancreatic cancer is extremely short, no more than 18% of patients can persist for more than one year, and patients with metastatic pancreatic cancer have a more limited life span. According to the survey, patients with pancreatic cancer worldwide have a life expectancy of only 2.7-5.8 months. I hope that the emergence of IMM-101 can help alleviate this dilemma. The results were published in the journal British Journal of Cancer. Source: Bio Valley VTM sampling kits are designed for the collection, preservation, and transport of viruses, chlamydia, mycoplasma, and ureaplasma urea. They are now widely used for sampling and transporting prior to virus detection. MandeLab's VTM kits provide a safe and convenient way to collect and transport virus samples. Nasal swab kit virus sampling tube,Used to collect samples of secretions from the throat or nasal cavity, Disposable Jiangsu iiLO Biotechnology Co., Ltd. , https://www.sjiilobiotech.com